chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Loud bang in chest 45 minutes after shot; First dose >35 days ago; This spontaneous case was reported by a consumer and describes the occurrence of CHEST DISCOMFORT (Loud bang in chest 45 minutes after shot) and PRODUCT DOSE OMISSION ISSUE (First dose >35 days ago) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Jan-2021, the patient experienced CHEST DISCOMFORT (Loud bang in chest 45 minutes after shot) and PRODUCT DOSE OMISSION ISSUE (First dose >35 days ago). At the time of the report, CHEST DISCOMFORT (Loud bang in chest 45 minutes after shot) and PRODUCT DOSE OMISSION ISSUE (First dose >35 days ago) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.  Treatment information was not provided.
This patient was given Varivax on 03/09/01 in the right thigh. On 03/22/01, the youngster erupted vesicular rash on the right leg. She had multiple small vesicular / papular covered right knee,thigh; patches vesicular papular over the abdomen, right lower leg. Vesicular erupted both hands and feet. Acyclovir on 04/11/01. Lesions began to resolve by 04/15/01. The follow up received on 5/18/01 states rash has since been diagnosed as papular acrodermatitis of childhood (Gianotti-Crosti syndrome).
Patient presented with 2 small pink slightly raised bumps on chin, each less than 1 mm in size. Patient denied shortness of breath, itching, or burning sensation. Torso and back with 8-10 fine raised bumps. Per protocol, 1 teaspoon oral Benadryl given. Rash began to subside. Patient continued to deny itching, pain, burning, or shortness of breath.
Palpitations (feeling of very strong heart beat ), chest pressure, worse with laying flat, shortness of breath, worse with exertion, fatigue, fever and brain fog.
No additional adverse events reported; improperly stored vaccines were potentially administered to unknown patients; This spontaneous report has been received from a licensed practical nurse, referring to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.    On 22-DEC-2021, the patient was vaccinated with improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (recombinant Human albumin (rHA)) (M-M-R II) (lot # T033815 with expiration date: 05-OCT-2022, route, strength and dose were unknown) for prophylaxis (Product storage error). No additional adverse events reported.  Administered dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (recombinant Human albumin (rHA)) (M-M-R II) experienced the temperature excursion below 49.6 Fahrenheit degrees (F) for 35 hours 9 minutes. The previous temperature excursions were reported as 32.9F for 53 hours 16 minutes; 49. 1F for 5 hours 9 minutes; 56.3F for 14 hours 7 minutes.  This is one of several reports received from the same reporter ; Sender's Comments:  US-009507513-2203USA003310: US-009507513-2203USA003311: US-009507513-2203USA003312: US-009507513-2203USA003313: US-009507513-2203USA003314: US-009507513-2203USA003315: US-009507513-2203USA003316: US-009507513-2203USA003317: US-009507513-2203USA003318: US-009507513-2203USA003319: US-009507513-2203USA003320: US-009507513-2203USA003321: US-009507513-2203USA003322: US-009507513-2203USA003323: US-009507513-2203USA003324: US-009507513-2203USA003325: US-009507513-2203USA003326: US-009507513-2203USA003327: US-009507513-2203USA003328: US-009507513-2203USA003329: US-009507513-2203USA003330: US-009507513-2203USA003331: US-009507513-2203USA003333: US-009507513-2203USA003334: US-009507513-2203USA003335: US-009507513-2202USA003592:
I started experiencing weak moments where I just felt weak on March 22nd I brought my bp machine with me to work when I had weak spells. I thought the bp machine was broken, I asked one of the Nurses at work to check and her reading was worse than what I had. She took me to a ER and about an hour and half later I was in a patient room with a temporary pace maker. They put me in the ICU and I stayed there until the evening of the 23rd  I was transported to Orlando Advent Health and they put a permanent pace maker in me. I spent the 23-24th in ICU 25th in cardiac care. I was released on the 26th
Mother stated within hours right arm reddened; sat patient c/o pain - pin pricks at site. Went to ER 9/30/07 when blisters formed.
Patient received their first dose on 24June 2021. Patient then came in and received their second dose on 13July2021, on day 19. Patient has had no adverse reactions. Patient has been notified of their early dosing.
positive Ag test 13Feb2023; covid test result=Positive; positive Ag test 13Feb2023; covid test result=Positive; This is a spontaneous report received from a non-contactable reporter(s) (Nurse).  A 39-year-old male patient received BNT162b2 (BNT162B2), on 27Jan2021 as dose 1, single (Lot number: EL3247), on 17Feb2021 as dose 2, single (Lot number: EL3247) and on 12Oct2021 as dose 3 (booster), single (Lot number: FF2589) at the age of 37 years for covid-19 immunisation. The patient's relevant medical history included: "covid-19" (unspecified if ongoing), notes: If covid prior vaccination: Yes. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 12Feb2023, outcome "unknown" and all described as "positive Ag test 13Feb2023; covid test result=Positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (13Feb2023) Positive, notes: Nasal Swab. It was unknown if therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical course: mild flu like sx 12Feb2023.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: As there is limited information in the case provided, the causal association between the reported events with the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available.
Next morning his left side of his face started dropping. Went to ER and they found Bell's Palsy and Vertigo. Went to ENT and an eye doctor.
On March 23 noticed a rash on upper part of Stomach; it continued to spread over my stomach, some on back and down to middle back part of leg;  went to doctor on March 29 - given Fluconazole - did not improve just kept spreading;  went back to doctor on April 9th - given a prescription of Methylprednisolone for 6 days:   Did clear by April 15h;  On both visits the doctor did not think it was from the vaccine shot but I felt it was important to report as this has not happened to me before.
I received my Covid -19 vaccine on 09/16/2022. On 11/25/2022 I was diagnosed with Covid -19. I woke up with a sore throat. Throughout the day I had chills and nasal congestion with an elevated temperature.  I called doctor and was prescribed medicine. On 12/09/2022 I still had symptoms of shortness of breath, chest tightness and coughing. sickness is ongoing.
Arm was red and swollen. Red rash on face also. Also got new med on same day making her very "loopy".
I had stomach discomfort and fatigue for several days after 2nd vaccine. Beginning August 9 liver enzymes were higher than normal for me.  At one point were alt 64 and ast 131. Latest were 9/20 alt 54 and 92. Before vaccine they were in the teens and 20's.
On 8/23/2022, I had chills symptoms. I took the COVID-19 home test on 8/24/2022 and the result was positive. I had chills and aches, cold sweats, I lost all my energy.  I had no appetite. I lost 10 pounds. I spent 4 days in bed. I did not sleep well. I took an anti-congestion. No sore throat. I never lost my sense of smell or taste. On 8/24/2022 I called my doctor and was prescribed the Paxlovid. I started taking it on 8/26/2022. On 8/31/2022, I tested negative.  On 9/1/2022 is when I started feeling a little better. 10/20/2022.  I have a lot of my energy back. I am trying to put the weight back on. I am on the road to recovery.
This case was considered medically important for the event of hypersensitivity. Information regarding PREVNAR 13 was received from a healthcare professional regarding a 3-year-old male patient who experienced felt stuck - unable to get up and walk, "acting really weird" and allergic reaction. At 3 years of age, the patient received the first dose on 29-Jul-2010. On 29-Jul-2010 the patient started "acting really weird" and coughing about 2 to 3 hours after PREVNAR 13 administration. Later that day he experienced felt stuck - unable to get up and walk. By the end of the night the child was wheezing. When he awoke on 30-Jul-2010 he experienced swollen eyes. He was brought to the doctor's office and diagnosed with an allergic reaction to PREVNAR 13 as evidenced by the coughing, wheezing and swollen eyes. He was treated with an oral dose of PRELONE and prescribed an EPIPEN. The outcome of these events was unknown. No additional information was available at the time of this report.
Severe upper shoulder into upper neck pain.  Epidural relieved pain by next day.  Then, severe thoracic pain with movement.  First epidural did not work, received second epidural on4/6/21.  No relief yet.  All pain medication my PCP tried did not relieve any pain.  Now I have very high blood pressure (once 202/103).  My normal BP is 120 or 130/70.  It is believed that the high BP is from the pain.
injection side turned red and swollen, measured at 7.5 x 5.5 cm and warm to touch. Fatigue, low grade fever at 100.9.
warm itchy hands approx 15mins post-vaccine - patient give a cetirizine 10mg tab
Pt. c/o minor HA, arm pain and tingling into hand on 4-22-13. Started with back pain on 4/23/13. Much worse 4-24-13 and 4/25/13. Back pain unknown etiology developing within 48 hours of GARDSIL.
Tightness in throat, urticaria face and neck, wheezing, periorbital swelling. Given IM Solumedrol and albuterol treatment.
Large knot in left upper arm, approximately 5" x 3.6" with tenderness, redness and hot to the touch. Aching in joints in arm/shoulder as well as into hip and legs. Symptoms appeared within few minutes of administration of vaccine.
Information has been received from a physician concerning a 2 month old female who on 10 Nov 2006 was vaccinated PO with a 2.0 mL dose of Rotateq (human bovine) (Lot #654352/0410F). The physician reported that on 16 Nov 2006, the patient developed diarrhea. Unspecified medical attention was sought and the patient tested negative for rotavirus. At the time of this report, the patient was noted to be recovering on therapy (not further specified). Additional information has been requested.
Fever: maximum temperature to 103 F 2 days post vaccine.  Neuropathy: bilateral foot pain on walking.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 25-OCT-2014, a pharmacist at a pharmacy administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On an unknown date in 2016, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
7JAN95 t101 w/pain, swelling @ local inj site along w/adenopathy; also nausea & vomiting; main complaint w/nausea & vomitting; MD prescribed ATB over the phone
high sensitivity to cold; chills; pain in the arm; This spontaneous case was reported by a consumer and describes the occurrence of FEELING COLD (high sensitivity to cold), CHILLS (chills) and PAIN IN EXTREMITY (pain in the arm) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Dec-2020, the patient experienced CHILLS (chills) and PAIN IN EXTREMITY (pain in the arm). On 11-Jan-2021, the patient experienced FEELING COLD (high sensitivity to cold). On 31-Dec-2020, CHILLS (chills) and PAIN IN EXTREMITY (pain in the arm) had resolved. At the time of the report, FEELING COLD (high sensitivity to cold) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment included ibuprofen.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Began having new onset joint pain/stiffness in February. Primary areas include bilateral hands, bilateral shoulders, bilateral hips. Increased fatigue, pain, and stiffness and difficulty with some activities prompted initial visit with PCP on April 14, 2021.  Was referred to rheumatologist with appointment on 8/3/2021--ordered multiple lab tests to assist with diagnosis. Short course of oral steroids prescribed. Follow-up visit in 6 weeks.
Soreness in arm, couldn't straighten, hot, red area, about the size on an adult hand on underside of arm, a few inches from injection site.
doses were given after expiration date; doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) and PRODUCT STORAGE ERROR (doses were given after expiration date) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (doses were given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) and PRODUCT STORAGE ERROR (doses were given after expiration date) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  Date the vial was initially stored in the refrigerator was 22-Sep-2021. There was no temperature excursion. The reporter reported that that there was a confusion between the expiration date printed in the carton and the expiration date when the QR code was scanned.  The patient did not experience any adverse event.  No treatment information was provided by the reporter.
Shot #1 of my vaccine was given at 12:20 on 2/16.  At 1 PM on 2/17 I went Lap swimming at the YMCA.  Normally I swim 52 laps but on 2/17 after only 46 laps I exited the pool after feeling nauseous.  I then vomited and then got dressed and went home.  I then vomited after being at home for only 1 hour. After calling a doctor I was advised to get lots of rest, stay on a BRAT diet and to take an anti-nausea medication.
About 13 hours after getting my second shot, I began feeling very lethargic, tired, achy, and sore.  I got the chills and then felt hot.  This continued through the night.  In the morning I couldn't get out of bed.  By about noon the following day (26 hours post vaccine), I began feeling better.  By 5pm, I was much improved.  By late evening and the next morning, I was back to normal.
No additional adverse effect reported; vaccine that underwent a temperature excursion was administered; This spontaneous report was received from a medical assistant referring to a patient on unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.  It was reported that Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (lot # T005400, expiration date was reported as 11-AUG-2021 but upon internal validation established as 12-AUG-2021; lot # T028138, expiration date was reported as 14-FEB-2022 but upon internal validation established as 15-FEB-2022; lot # T025509, expiration date was reported as 22-JAN-2022 but upon internal validation established as 23-JAN-2022; lot # T025510, expiration date was reported as 22-JAN-2022 but upon internal validation established as 23-JAN-2022) underwent a temperature excursion.  11-JUN-2021, the patient was vaccinated with an improperly stored dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (dose and route were not reported) for prophylaxis. Information for which lots were given to patient not provided. The vaccine was exposed the temperature excursion above 7.3 Fahrenheit degrees (F) (6 F to 14 F) for 10 minutes (product storage error). The data logger was involved. There was no previous temperature excursion. No adverse effects were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2106USA004356:
This spontaneous report was received from a licensed vocational nurse  and refers to a 12 month old male patient. There were no concurrent conditions, concomitant therapies and medical history. On 21-DEC-2016, around 15:00, the patient was vaccinated with a dose of PROQUAD 0.5 ml injection, 0.5 ml once, which had a lot # of L016393, an expiration date of 08-NOV-2016, as need for measles, mumps, rubella and varicella (MMRV) vaccine. The patient did not experienced adverse events. Additional information has been requested.
This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer Expired vaccine) in a 30-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On 02-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer Expired vaccine). On 02-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Administer Expired vaccine) had resolved. Not Provided. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. The vaccine was administered to the from 20Oct2021 to 29Nov2021. Lot number of vial was 006C21 (10Feb2021), 026B21A (17Sep2021), 031B21A (22Sep2021). No treatment was given to the patients. No concomitant medications were reported.
Injection site pain (immediate), muscle pain (12 hours after), dizziness (15 hours after).
This spontaneous report as received from a program manager (also reported as Health care worker) refers to multiple patients of unknown demographics. The patients medical history and historical conditions are not reported. It was reported that on an unknown date the patients were vaccinated with GARDASIL (unknown strength, dose and frequency) that was stored improperly. No product quality complaint was reported. The outcome of the event is unknown. This is one of the several reports received from the same reporter. Additional information has been requested.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and drug allergies were not reported. On 17-JUL-2017 the patient was vaccinated with both VARIVAX, 1 dose unit (Lot # M029918, Expiry date: 28-SEP-2018) and PROQUAD 1 dose unit (Lot # N013865, Expiry date: 31-OCT-2018) for prophylaxis (inappropriate schedule of drug administration). Concomitant therapies included sterile diluent, lot # and expiry date was unknown. No adverse effects were reported. There was no product quality complaint involved. This is 1 of the 2 reports from the same reporter. Lot N013865 is a valid lot number for PROQUAD and has been added to the lot number field. Lot M029918 is an invalid lot number for VARIVAX. Sender's Comments: US-009507513-1707USA008603.
2 cm by 2cm red area with mild industries on right thigh, nonfade, not warm.
SORE ARM; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) .5 ml, start therapy date was not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the Patient  experienced sore arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of sore arm was not reported. This report was non-serious. This case, from the same reporter is linked to 20210519940.
vaccine hurts; This case was reported by a consumer via  media and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient reported that the Shingles vaccine hurts. The patient enquired that the vaccine probably did not hurt as bad as shingles. The follow-up would not possible as no contact details were available.
Rash similar to poison ivy on shoulder arm and side of neck from injection site upward. Only one one side. Not itchy so far and seems to not even bother him. He did have a little headache.
pt recv vax 23OCT96 & next day 24OCT96 devel cellulitis around the inj site;